1. A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates
- Author
-
Rennard, Stephen, Hughes, John, Cinciripini, Paul M., Kralikova, Eva, Raupach, Tobias, Arteaga, Carmen, St Aubin, Lisa B., Russ, Cristina, Marta, Angueira, Elie, Fiss, Claude, Gagne, Helmersen, Douglas S., Ping, Chen, Rong Chang Chen, Chen, Wang, Czech, Beatrice Le Maitre, Isabelle, Schenkenberger, Iren, Herjavecz, Maria, Szilasi, Carrozzi, Laura, Rodolfo, Posadas, Ho Joong Kim, Young Whan Kim, Huey Shinn Cheng, Kuang Chieh Hsueh, Alex, Bobak, Anderson, Corey G., Borders, James L., Victor, Alan, Johnson, Gary E., Nabil Charle Morcos, Puopolo, Anthony D., Jon Andrew Shapiro, Sharp, Stephan C., Mark Edward Shirley, Tashkin, Donald P., and Vince, Bradley D.
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Placebo-controlled study ,Original Investigations ,Placebo ,Drug Administration Schedule ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Quinoxalines ,Internal medicine ,Clinical endpoint ,Humans ,Medicine ,Nicotinic Agonists ,030212 general & internal medicine ,Adverse effect ,Varenicline ,Psychiatry ,business.industry ,Environmental and Occupational Health ,Public Health, Environmental and Occupational Health ,Odds ratio ,Benzazepines ,Middle Aged ,Tobacco Use Cessation Devices ,3. Good health ,Smoking Cessation ,Tobacco Use Cessation Products ,chemistry ,Smoking cessation ,Smoking ,Public Health ,business ,030217 neurology & neurosurgery - Abstract
INTRODUCTION: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication. METHODS: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24. RESULTS: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2% varenicline (none were psychiatric) and 0.6% placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3% vs. 6.7%, respectively). CONCLUSIONS: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies. peerReviewed
- Published
- 2011